Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4290-4299

  Donalisio, Manuela ^a   Rusnati, Marco ^b   Civra, Andrea ^a   Bugatti, Antonella ^b   Allemand, Donatella ^c   Pirri, Giovanna ^c   Giuliani, Andrea ^c   Landolfo, Santo ^a   Lembo, David ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Spider Biotech Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DENDRIMER; HEPARAN SULFATE; MICROBICIDE; PEPTIDE; PEPTIDE DENDRIMER SB105 A10; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL SURFACE; CLUSTER ANALYSIS; CONDYLOMA ACUMINATUM; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS INFECTIVITY; VIRUS INHIBITION; WART VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; DENDRIMERS; HELA CELLS; HEPARITIN SULFATE; HUMANS; INHIBITORY CONCENTRATION 50; MICROSCOPY, ELECTRON, TRANSMISSION; PAPILLOMAVIRIDAE; PEPTIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURFACE PLASMON RESONANCE;

EID: 77957371320     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00471-10     Document Type: Article

References (58)

1. Abramowitz, L., D. Benabderrahmane, P. Ravaud, F. Walker, C. Rioux, C. Jestin, E. Bouvet, J. C. Soule, C. Leport, and X. Duval. 2007. Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS 21:1457-1465. (Pubitemid 46988006)
2. Barth, H., E. K. Schnober, F. Zhang, R. J. Linhardt, E. Depla, B. Boson, F. L. Cosset, A. H. Patel, H. E. Blum, and T. F. Baumert. 2006. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J. Virol. 80:10579-10590.
3. Boas, U., and P. M. H. Heegaard. 2004. Dendrimers in drug research. Chem. Soc. Rev. 33:43-63.
4. Bosch, F. X., and S. de Sanjose. 2003. Human papillomavirus and cervical cancer - burden and assessment of causality. J. Natl. Cancer Inst. Monogr. 31:3-13.
5. Bourne, N., L. R. Stanberry, E. R. Kern, G. Holan, B. Matthews, and D. L. Bernstein. 2000. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob. Agents Chemother. 44:2471-2474.
6. Bousarghin, L., A. Touze, L. Combita-Rojas, and P. Coursaget. 2003. Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. J. Gen. Virol. 84:157-164.
7. Buck, C. B., N. Cheng, C. D. Thompson, D. R. Lowy, A. C. Steven, J. T. Schiller, and B. L. Trus. 2008. Arrangement of L2 within the papillomavirus capsid. J. Virol. 82:5190-5197.
8. Buck, C. B., C. D. Thompson, J. N. Roberts, M. Muller, D. R. Lowy, and J. T. Schiller. 2006. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2:e69.
9. Buck, C. B., D. V. Pastrana, D. R. Lowy, and J. T. Schiller. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78:751-757.
10. Buck, C. B., D. V. Pastrana, D. R. Lowy, and J. T. Schiller. 2005. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119:445-462.
11. Bugatti, A., P. Chiodelli, J. Rosenbluh, A. Loyter, and M. Rusnati. 2010. BSA conjugates bearing multiple copies of the basic domain of HIV-1 Tat: prototype for the development of multitarget inhibitors of extracellular Tat. Antiviral Res. 87:30-39.
12. Bugatti, A., C. Urbinati, C. Ravelli, E. De Clercq, S. Liekens, and M. Rusnati. 2007. Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Antimicrob. Agents Chemother. 51:2337-2345.
13. Byrnes, A. P., and D. E. Griffin. 1998. Binding of Sindbis virus to cell surface heparan sulfate. J. Virol. 72:7349-7356.
14. Check, E. 2007. Scientists rethink approach to HIV gels. Nature 446:12.
15. Chen, Y., T. Maguire, R. E. Hileman, J. R. Fromm, J. D. Esko, R. J. Linhardt, and R. M. Marks. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866-871.
16. Christensen, N. D., C. A. Reed, T. D. Culp, P. L. Hermonat, M. K. Howett, R. A. Anderson, and L. J. Zaneveld. 2001. Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrob. Agents Chemother. 45:3427-3432.
17. Christensen, N. D., N. M. Cladel, and C. A. Reed. 1995. Postattachment neutralization of papillomaviruses by monoclonal and polyclonal antibodies. Virology 207:136-142.
18. Cloniger, M. J. 2002. Biological applications of dendrimers. Curr. Opin. Chem. Biol. 6:742-748.
19. Day, M. D., R. Gambhira, R. B. S. Roden, D. R. Lowy, and J. T. Schiller. 2008. Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J. Virol. 82:4638-4646.
20. de Haan, C. A., Z. Li, E. te Lintelo, B. J. Bosch, B. J. Haijema, and P. J. Rottier. 2005. Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor. J. Virol. 79:14451-14456.
21. de Villiers, E. M., C. Fauquet, T. R. Broker, H. U. Bernard, and H. zur Hausen. 2004. Classification of papillomaviruses. Virology 324:17-27.
22. Ernst, S., R. Langer, C. L. Cooney, and R. Sasisekharan. 1995. Enzymatic degradation of glycosaminoglycans. Crit. Rev. Biochem. Mol. Biol. 30:387-444.
23. Esko, J. D. 1991. Genetic analysis of proteoglycan structure, function and metabolism. Curr. Opin. Cell Biol. 3:805-816.
24. Feldman, S. A., S. Audet, and J. A. Beeler. 2000. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J. Virol. 74:6442-6447.
25. Giroglou, T., L. Florin, F. Schafer, R. E. Streeck, and M. Sapp. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75:1565-1570. (Pubitemid 32094716)
26. Goldfarb, D. S., J. Gariepy, G. Schoolnik, and R. D. Kornberg. 1986. Synthetic peptides as nuclear localization signals. Nature 322:641-644.
27. Grulich, A. E., M. T. van Leeuwen, M. O. Falster, and C. M. Vajdic. 2007. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59-67.
28. Harper, D. M., E. L. Franco, C. Wheeler, D. G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, N. S. De Carvalho, C. M. Roteli-Martins, J. Teixeira, M. M. Blatter, A. P. Korn, W. Quint, G. Dubin, and GlaxoSmithKline HPV Vaccine Study Group. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 364:1757-1765.
29. Harris, J. R., W. Gebauer, and J. Markl. 1995. Keyhole limpet haemocyanin: negative staining in the presence of trehalose. Micron 26:25-33.
30. Holmes, K. K., R. Levine, and M. Weaver. 2004. Effectiveness of condoms in preventing sexually transmitted infections. Bull. World Health Organ. 82:454-461.
31. Honey, K. 2007. Microbicide trial screeches to a halt. J. Clin. Invest. 117:1116.
32. Howley, P. M., and D. R. Lowy. 2001. Papillomaviruses and their replication, p. 2197-2229. In B. N. Fields et al. (ed.), Fields virology. Lippincott-Raven, Philadelphia, PA.
33. Jackson, T., F. M. Ellard, R. A. Ghazaleh, S. M. Brookes, W. E. Blakemore, A. H. Corteyn, D. I. Staurt, J. W. Newman, and A. M. King. 1996. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J. Virol. 70:5282-5287.
34. Johnson, K. M., R. C. Kines, J. N. Roberts, D. R. Lowy, J. T. Schiller, and P. M. Day. 2009. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J. Virol. 83:2067-2074.
35. Joyce, J. G., J. S. Tung, C. T. Przysiecki, J. C. Cook, E. D. Lehman, J. A. Sands, K. U. Jansen, and P. M. Keller. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274:5810-5822.
36. Kines, R. C., C. D. Thompson, D. R. Lowy, J. T. Schiller, and P. M. Day. 2009. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. U. S. A. 106:20458-20463.
37. Lacey, C. J., C. M. Lowndes, and K. V. Shah. 2006. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24(Suppl. 3):S35-S41.
38. Lee, E., R. A. Hall, and M. Lobigs. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J. Virol. 78:8271-8280. (Pubitemid 38944311)
39. Lembo, D., M. Donalisio, M. Rusnati, A. Bugatti, M. Cornaglia, P. Cappello, M. Giovarelli, P. Oreste, and S. Landolfo. 2008. Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus. Antimicrob. Agents Chemother. 52:1374-1381.
40. López, S., and C. F. Arias. 2004. Multistep entry of rotavirus into cells: a Versaillesque dance. Trends Microbiol. 12:271-278.
41. Lowy, D. R., and P. M. Howley. 2001. Papillomaviruses, p. 2231-2264. In B. N. Fields et al. (ed.), Fields virology. Lippincott-Raven, Philadelphia, PA.
42. Luganini, A., A. Giuliani, G. Pirri, L. Pizzuto, S. Landolfo, and G. Gribaudo. 2010. Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate. Antiviral Res. 85:532-540.
43. Manhart, L. E., and L. A. Koutsky. 2002. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex. Transm. Dis. 29:725-735.
44. Niederhafner, P., S. Jaroslav, and J. Jan. 2005. Peptide dendrimers. J. Pept. 12:757-788.
45. Nikolic, D. S., and V. Piguet. 2010. Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission. J. Invest. Dermatol. 130:352-361.
46. Patel, M., M. Yanagishita, G. Roderiquez, D. C. Bou-Habib, T. Oravecz, V. C. Hascall, and M. A. Norcross. 1993. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retroviruses 9:167-174.
47. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Hederwijin, J. Desmyter, and E. De Clerq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti HIV compounds. J. Virol. Methods 20:309-321.
48. Rupp, R., S. L. Rosenthal, and L. R. Stanberry. 2007. VivaGel™ (SPL7013 gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int. J. Nanomed. 4:561-566.
49. Rusnati, M., C. Urbinati, A. Caputo, L. Possati, H. Lortat-Jacob, M. Giacca, D. Ribatti, and M. Presta. 2001. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J. Biol. Chem. 276:22420-22425.
50. Rusnati, M., E. Vicenzi, M. Donalisio, P. Oreste, S. Landolfo, and D. Lembo. 2009. Sulfated K5 Escherichia coli polysaccharide derivatives: a novel class of candidate antiviral microbicides. Pharmacol. Ther. 123:310-322.
51. Sadler, K., and J. P. Tam. 2002. Peptide dendrimers: applications and synthesis. J. Biotechnol. 90:195-229.
52. Schiller, J. T., X. Castellsagué, L. L. Villa, and A. Hildesheim. 2008. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26(Suppl. 10):K53-K61.
53. Shafti-Keramat, S., A. Handisurya, E. Kriehuber, G. Meneguzzi, K. Slupetzky, and R. Kirnbauer. 2003. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77:13125-13135. (Pubitemid 37494308)
54. Shukla, D., and P. G. Spear. 2001. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J. Clin. Invest. 108:503-510.
55. Skoler-Karpoff, S., G. Ramjee, K. Ahmed, L. Altini, M. G. Plagianos, B. Friedland, S. Govender, A. De Kock, N. Cassim, T. Palanee, G. Dozier, R. Maguire, and P. Lahteenmaki. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977-1987.
56. Spillmann, D. 2001. Heparan sulfate: anchor for viral intruders? Biochimie 83:811-817.
57. Tyagi, M., M. Rusnati, M. Presta, and M. Giacca. 2001. Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276:3254-3261.
58. Villa, L. L., R. L. Costa, C. A. Petta, R. P. Andrade, K. A. Ault, A. R. Giuliano, C. M. Wheeler, L. A. Koutsky, C. Malm, M. Lehtinen, F. E. Skjeldestad, S. E. Olsson, M. Steinwall, D. R. Brown, R. J. Kurman, B. M. Ronnett, M. H. Stoler, A. Ferenczy, D. M. Harper, G. M. Tamms, J. Yu, L. Lupinacci, R. Railkar, F. J. Taddeo, K. U. Jansen, M. T. Esser, H. L. Sings, A. J. Saah, and E. Barr. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271-278.